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Background: Castleman-Kojima disease (TAFRO Syndrome) is characterized by Thrombocytopenia, Anasarca,
myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical
Castleman’s disease (CD). Only few cases of this recently identified unique variant of Multicentric CD (MCD) are
described in literature, all Japanese. It therefore poses serious diagnostic and therapeutic challenges.
Case description: We describe a 21 year old woman with fever, asthenia, bilateral pleural effusion, ascites,
hypoalbuminemia, severe thrombocytopenia, anemia, renal failure and proteinuria, whereas microbiological
tests, immune serology (except ANA) and bone marrow biopsy were all negative. A CT-scan showed multiple
lymphadenopathy and tissue samplings of mediastinal lymph nodes was compatible with a mixed-type CD. The
diagnosis of MCD with TAFRO syndrome was made, but after an initial improvement with high dose corticosteroid
therapy, clinical and laboratory features worsened. Based upon the high serum IL-6 levels and the high number of
CD20-lymphocytes in lymph nodes tissue, we started tocilizumab (partial benefit), followed by rituximab combined
with CVP (cyclophosphamide, vincristine and prednisone) chemotherapy, achieving a complete response. A total
of six cycles of R-CVP were administered monthly, followed by maintenance with monthly rituximab.
A complete remission persists at the 12th month of follow-up.
Conclusions: In patients with massive immune system activation and lymphadenopathy it is mandatory to rule
out Castleman-Kojima disease. In our patient a therapy aimed at the prominent pathophysiological abnormalities
has been successful so far. However, since the rarity of TAFRO Syndrome, a multicenter registry is strongly desirable
for a better understanding of the disease mechanisms, hopefully leading to evidence-based therapeutic choices.
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Castleman-Kojima disease (TAFRO Syndrome) is a novel
systemic inflammatory disorder characterized by a con-
stellation of symptoms, namely, thrombocytopenia, ana-
sarca, myelofibrosis, renal dysfunction and organomegaly,
and multiple lymphadenopathy of mild degree with histo-
pathology of mixed- or hyaline vascular-type Castleman’s* Correspondence: pomponio@univpm.it
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unless otherwise stated.disease (CD). This unique clinicopathologic variant of
Multicentric CD (MCD) has been recently identified in
Japan [1] and poses serious diagnostic and therapeutic
challenges for pathologists and clinicians, including the
differential diagnosis from autoimmune diseases.
Two are the main peculiarities of the case we herein
describe: 1. This is the first report of a Caucasian pa-
tient; 2. The patient has been successfully treated with a
combination therapy of immunosuppressive and cyto-
toxic drugs.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Case description
A 21 year old Caucasian woman with no relevant medical,
family or psychosocial history was admitted to our depart-
ment for pleural and pericardium effusion and ascites.
The patient had been experiencing left subcostal pain,
dyspnea and general malaise for four weeks before admis-
sion. She presented fever (38.5°C) with shiver, pharyngo-
dynia, periorbital edema and asthenia (Table 1). One week
before admission she visited a local hospital where she
underwent a series of medical tests. Laboratory results
revealed blood count abnormalities (thrombocytopenia
and normocytic anemia), hypoalbuminemia, elevation of
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), ferritin and γ-globulin (polyclonal) (Table 2). Ab-
dominal ultrasonography showed hepato-splenomegaly
with ascites, while a chest radiography and an echo-
cardiography detected bilateral pleural and pericardial
effusion. She was then referred to Ancona University
Hospital for further diagnostic assessments.
On admission, she was dyspnoic and febrile (37.8°); a
severe pitting edema was evident in both legs and the
abdomen wall was markedly outstretched due to ascites.
No skin lesions were visible. Her superficial lymph nodes
were not palpable.Table 1 Patient and disease characteristics at onset
Somatic features Caucasian female, 21 years old
Genetic features and family
history
Negative
Past medical history Isolated seizure in childhood (age 15)
Car accident with right femur fracture
(age 17)









White blood cells 11.8 × 103/μL
Hemoglobin 11.5 g/dL
Platelet counts 29 × 103/μL
AST 56 IU/L
Albumin 1.86 g/dL
Proteinuria 0.47 g/24 h
CRP 22.2 mg/dL
Ferritin 715 ng/mL
Reference ranges and abbreviations. White blood cells: 4–10 × 103/μL;
Hemoglobin: 11.5-16 g/dL; Platelet counts: 150-400 × 103/μL; AST (aspartate
aminotransferase): 0–40 IU/L; Albumin: 3.7-5.5 g/dL; Proteinuria: < 0.15 g/24 h;
CRP (C reactive protein): 0–0.6 mg/dL; Ferritin 12–180 ng/mL.Further laboratory tests revealed mild renal failure and
significant proteinuria, whereas repeated blood, periton-
eum liquid and urine coltural samples were sterile. Anti-
Toxoplasma, anti-Bartonella, anti-Rickettsia antibodies and
Widal-Wright test were all negative, as well as anti-HIV,
anti-CMV, hepatitis C virus antibodies and hepatitis B sur-
face antigen test. Moreover, PCR tests did not detect the
presence of Epstein-Barr Virus DNA nor HHV-8 in the
patient’s blood. Immune serology (anti-nDNA, anti-ENA,
aCL, anti-β2GPI, ANCAs) were all negative. ANA were de-
tected (1/640, granular pattern). The serum complement
levels were normal. No monoclonal bands were observed
on immunofixation tests. A bone marrow biopsy revealed
a diffuse and dense increase in reticulin with reactive
hyperplastic pattern (Figure 1A,B), and a mononuclear
cells immunophenotyping was substantially normal. The
serum level of IL-6 was significantly higher than normal:
19.4 pg/mL (reference range 0–5.2 pg/mL).
After admission, a continuous fever ranging between
37.5° and 38°C persisted, and platelet, albumin and red
blood cell transfusions were required. Additionally, the pa-
tient’s renal function rapidly deteriorated, with increased
proteinuria. A whole body computed tomography (CT)
showed bilateral axillar, mediastinal and abdominal para-
aortic, celiac and perisplenic lymph nodes, hepatospleno-
megaly, pleural and peritoneal effusion (Figure 2A,C).
The ascites and pleural fluids had biochemical exuda-
tive characteristics but were sterile, and no lymphoma or
other malignant cells were detected in the samples.
Tissue samplings of inguinal and mediastinal nodules
(by bronchoscopy) were not diagnostic. After an initial
improvement with high dose steroid therapy (methylpred-
nisolone intravenously at 1 mg/kg for two weeks, then
prednisone 50 mg/d orally, tapered to 37.5 mg/d), clinical
and lab features worsened. A surgical mediastinal lymph
node biopsy finally showed an histological picture sugges-
tive for mixed-type (hyaline-vascular and plasma cell type)
Castleman’s disease (Figure 1C,D).
The diagnosis of Multicentric Castleman’s Disease
with TAFRO syndrome was then established.
Given the high plasmatic level of IL-6 and the clinical
evidences available in literature, we added tocilizumab
(8 mg/kg intravenously, every two weeks, three infusions)
to the corticosteroid therapy (prednisone 50 mg/d orally);
some of the patient’s features improved (Table 2), but after
one month, there was no further clinic or laboratoristic
benefit. Therefore, R-CVP (rituximab 375 mg/m3, cyclo-
phosphamide 750 mg/m3, vincristine 1.4 mg/m3 and
prednisone 40 mg/m3) chemotherapy was started (CVP
monthly; rituximab weekly for the first month, then
monthly). Two days after the first infusion a severe
Posterior Reversible Encephalopathy Syndrome (PRES),
clinically characterized by hypertension, visual distur-
bances, severe headache and convulsive crisis, appeared.
Table 2 Laboratory data of the patient
At the onset
of disease
















11.8 15.9 26.6 12.9 20.9 7.5 8
Hemoglobin (g/dL) 11.5 8.9 6.3 13.2 8 14.7 13.9
MCV (fL) 90.7 85 86 102 92 97.5 97
Platelet counts
(×103/μL)
29 7 11 84 16 295 279
AST (IU/L) 56 104 16 25 19 17 12
ALT (IU/L) - 67 18 34 71 10 9
LDH (IU/L) 340 637 552 630 824 - -
Albumin (g/dL) 1.86 1.87 2.2 3 2.4 3.83 3.87
Creatinine (mg/dL) 0.8 1.6 1.3 0.6 0.9 0.6 0.6
Proteinuria (g/24 h) 0.47 1.96 4.52 0.9 1.21 0.1 0
CRP (mg/dL) 22.2 28.3 17.2 0.1 5.1 0.1 0.1
Ferritin (ng/mL) 715 1097 1126 - 1427 294 281
IL6 (pg/mL) - 19.4 8.8 1.5 2.3 3 1
Reference ranges and abbreviations. White blood cells: 4–10 × 103/μL; Hemoglobin: 11.5-16 g/dL; MCV (mean corpuscular volume): 80–98 fL; Platelet counts:
150-400 × 103/μL; AST (aspartate aminotransferase): 0–40 IU/L; ALT (alanine aminotransferase): 0–40 IU/L; LDH (lactate dehydrogenase): 0–450 IU/L; Albumin:
3.7-5.5 g/dL; Creatinine: 0.6-1.4 mg/dL; Proteinuria: < 0.15 g/24 h; CRP (C reactive protein): 0–0.6 mg/dL; Ferritin 12–180 ng/mL; IL6 (interleukin 6): 0-5-2 pg/mL);
TCZ: tocilizumab 8 mg/kg; R-CVP: rituximab 375 mg/m3, cyclophosphamide 750 mg/m3, vincristine 1.4 mg/m3 and prednisone 40 mg/m3.
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enlargement of brain cerebrospinal fluid spaces and some
small cortical-subcortical areas of altered signal. The syn-
drome resolved without any aftermath after three days.
An anti-hypertensive and anti-comitial prophylaxis was
added, the cyclophosphamide dose was reduced to 50%
only in the second administration and the patient com-
pleted a total of 6 chemotherapy cycles without other
adverse events.
Seven months after disease onset, a CT scan revealed
no ascites or pleural effusion and reduction of lympha-
denopathy (Figure 2B,D). After the sixth infusion (nine
months from the disease onset), the patient’s symptoms
had completely disappeared and blood tests, including
the serum IL6 level, were within the normal range.
Steroid therapy was carefully tapered during chemo-
therapy period and then discontinued. A single infusion of
rituximab 375 mg/m3 is currently administered monthly as
maintenance therapy.
Twelve months after disease onset the patient continues
to be totally asymptomatic and a 18-fluoro-deoxyglucose
(FDG) positron emission tomography (PET) scan did
not show any evidence of pathologic hyper-accumulation
areas to be referred to disease activity. Clinical course and
main diagnostic and therapeutic procedures are summa-
rized in Figure 3.
Discussion
In a recent Japanese consensus conference [1], a new clas-
sification of MCD based on clinical and hystopatologicalfeatures distinguished the Idiopathic Plasmacytic Lympha-
denopathy (IPL)-type, either HHV8 positive or negative,
from the non-IPL variants. TAFRO syndrome, POEMS
syndrome, HIV-associated CD, malignant lymphoma-
associated CD and IgG4-related diseases are the main
entities of the latter (Figure 4).
The TAFRO syndrome, that in the past may have been
occasionally described under a MCD label (even in
Caucasian patients [3]), is characterized by a constellation
of symptoms resembling the most severe autoimmune
diseases (Systemic Lupus Erythematosus -SLE- or sys-
temic vasculitis) and because of the nonspecific manifesta-
tions at onset, a careful and prolonged follow-up is often
needed to reach a definitive diagnosis and to start the
treatment.
A review of the literature with sensible strategy was per-
formed. Both PubMed and Embase databases were
searched, with “tafro [All Fields] AND (“syndrome” [MeSH
Terms] OR “syndrome” [All Fields])” and “Multi-centric
Castleman’s Disease [Supplementary Concept]” as strategy.
Manual search was added and 30 pertinent articles were
found (last update July 2014). The research showed, after
the identification of this unique variant of MCD, only a
handful of TAFRO cases, all in Japan, treated with toci-
lizumab and/or rituximab and cyclosporine A [4-9], with
discordant results. A standard therapy is therefore far to be
established and a therapeutic strategy borrowed from the
MCD experience is suggested [10].
Since the disseminated lymphadenopathy rarely enable
complete surgical debulking [11,12], patients with MCD
Figure 1 Histopathological findings. (A) The bone marrow appeared hypercellular with a marked expansion of granulopoiesis and a moderate
increase of megakaryocytes (Periodic acid–Schiff (PAS), 20X). (B) On sections stained with the Gomori's silver impregnation technique, a diffuse
and dense increase in reticulin with extensive intersections, occasionally with only focal bundles of collagen was evident. Fiber density was
considered as grade 2 according to the European Consensus Criteria for grading myelofibrosis by Thiele et al. [2] (20X). (C,D) Multiple fragments
of lymph node tissue were excised from the mediastinum of this patient. The architecture was preserved, showing CD20+ B-follicles and germinal
centers with onion-skin appearance around prominent arterioles. The interfollicular areas showed abundant plasma cells with normal kappa:
lambda ratio. Immunohistochemistry did not reveal aberrant B- or T-cell phenotype. Molecular testing was negative for B-cell or T-cell monoclonality.
The search for HHV8 and EBV was also negative. The histology pattern was considered not diagnostic for malignant lymphoma and related to a
lymphadenopathy with features resembling multicentric Castleman’s disease. The diagnosis was reviewed at the referral center of Bologna (Prof. Pileri)
and confirmed.
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commonly used, and a response rate of 60% has been
achieved, although responses are transient [8].
Due to the role of IL-6 in the pathogenesis of CD,
antibodies against its receptor have been used [14]. In
several reported cases [6,15,16] tocilizumab was very ef-
fective: patients achieved a complete remission and the
treatment was discontinued often without disease recur-
rence [17].
Moreover, anti-CD20 monoclonal antibody (rituximab)
has increasingly been used as a front-line treatment in
most chronic B-cell lymphoproliferative disorders, in
combination with standard chemotherapeutic regimens.
Some reports of its efficacy in MCD have been published
[18,19], both in HHV-8 negative and HHV-8 positive pa-
tients, alone [9] or in association with combined chemo-
therapy [20].
Finally, in MCD patients treated with lymphoma-
based chemotherapy, such as cyclophosphamide, vin-
cristine, doxorubicin, and either prednisone (CHOP) or
dexamethasone (CVAD), the overall response rate is
around 90%, with 50% complete responses, but relapses
are common and the median survival around 19 months.Durable responses occur approximately in 25% of cases,
and rare remissions have been sustained in excess of
15 years [21].
However, when to start chemotherapy, how many cy-
cles are required and the role of an eventual main-
tenance therapy need to be further investigated.
In the present case, a pathophysiology-targeted treatment
was chosen. Based upon the high IL-6 levels in the serum,
steroid therapy was initially associated to tocilizumab. Be-
cause of the high number of CD20-lymphocytes in lymph
nodes tissue, rituximab combined with CVP chemothe-
rapy followed, obtaining a complete clinical and biological
response. Furthermore, a maintenance therapy with rituxi-
mab 375 mg/m3 monthly has appeared to be effective and
safe after a six months follow-up (first description in
literature).
Moreover this case points out another rare condition,
that is Posterior Reversible Encephalopathy Syndrome
(PRES) [22,23], a poorly understood and described
clinical-radiological syndrome whose pathogenesis has
been ascribed to altered cerebral circulation and endothe-
lial dysfunction. Many immunosuppressive drugs, such as
intravenous immunoglobulin, ciclosporin A, tacrolimus,
Figure 2 CT images. (A, B) Contrast enhanced thoracic computed tomography (CT) before (A) and after (B) six months of chemotherapy,
showing resolution of pleural effusion and the shrinking of axillar and mediastinal lymphnodes. (C, D) Contrast enhanced abdominal CT before
(C) and after (D) six months of chemotherapy, showing the reduction of hepato-splenomegaly and celiac and perisplenic lymphadenopathy.
Figure 3 Patient’s disease course (12 months-follow-up). CT: computed tomography; MRI: magnetic resonance imaging; PET: positron
emission tomography; TCZ: tocilizumab 8 mg/kg; R-CVP: rituximab 375 mg/m3, cyclophosphamide 750 mg/m3, vincristine 1.4 mg/m3 and prednisone
40 mg/m3; RTX: rituximab 375 mg/m3; Hb: hemoglobin; PLT: platelet counts; CRP: C reactive protein; IL6: interleukin 6.
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Figure 4 New classification of MCD based on clinical and hystopatological features. Modified from: Kawabata H, et al. Castleman-Kojima
disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia,
ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly : a status report and summary of Fukushima (6 June,
2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 2013, 53(1):57–61. IPL: Idiopathic Plasmacytic Lymphadenopathy; POEMS:
Polyneuropathy, Organomegaly, Endocrinopathy/Edema, M-protein, Skin abnormalities; TAFRO: Thrombocytopenia, Anasarca, myeloFibrosis, Renal
dysfunction and Organomegaly.
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may be responsible for this syndrome. The most novel
finding in recent clinical series is the high prevalence
of autoimmune disorders, especially SLE [24]. Although
PRES is not considered an autoimmune condition per se,
the association with immunological diseases suggests that
endothelial dysfunction may lie at the core of its patho-
physiology. Further research is of course needed to assess
the merit of this hypothesis.
Conclusions
In conclusion, this is the first reported Caucasian case of
MCD with TAFRO syndrome. To achieve a more precise
definition of this novel entity, to establish criteria for diag-
nosis and to define a therapeutic strategy, as well as to bet-
ter investigate the etiology of MCD also in non-Japanese
patients, multicenter surveys are desirable. In the mean-
time, it is crucial that in patients with massive immune
system activation and lymphadenopathy, without any
known autoimmune diseases or other well-defined
lymphoproliferative disorders, Castleman-Kojima disease
should be suspected [5], especially if anasarca and ascites are
present. In the absence of solid clinical evidence about efficacy
of a specific therapeutic intervention, a pathophysiology-
based treatment could be reasonable and effective.
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